IPAR

Public Assessment Report for a
Medicinal Product for Human Use

Scientific Discussion

Perrigo Cold & Flu Multi-Relief CapsulesParacetamol 500mg, Guaifenesin 100mg, Phenylephrine 6.1mg
Paracetamol
Guaifenesin
Phenylephrine hydrochloride
PA1186/021/002

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

I. INTRODUCTION

This product was initially authorised under procedure number UK/H/1128/001/DC with the UK as RMS. The responsibility of RMS was transferred to Ireland on 17th May 2019 under procedure number IE/H/0902/001/DC.

Please note the following detail for the product in IE:
Marketing Authorisation Number: PA1186/021/002
Marketing Authorisation Holder: Chefaro Ireland DAC

The current Summary of Product Characteristics (SmPC) for this medicinal product is available on the HPRA website at www.hpra.ie.

The UK public assessment report published at the time of the initial marketing authorisation is provided herein.

Scientific discussion during initial procedure

RECOMMENDATION

Based on the review of the data on quality, safety and efficacy, the RMS considers that the application for Beechams Ultra All in One Capsules, is approvable.

The proposed indications are:

For the relief of symptoms associated with colds and flu and the pain and congestion of sinusitis, including aches and pains, headache, blocked nose and sore throat, chills, lowering of temperature, and to loosen stubborn mucous and provide relief from chesty coughs.

The maximum daily recommended dosages for this product are 8 capsules in adults and children aged 12 years and over. The product is not considered suitable for children under 12 years old because the content of paracetamol exceeds the maximum strength for GSL sale in the UK for use in children.

EXECUTIVE SUMMARY

Problem statement

Cough, mild pain, nasal congestion are common symptoms associated with the common cold and flu. The use of paracetamol, guaifenesin and phenylephrine has been well established in the treatment of these symptoms. Their uses alone or in combination in the proposed indications are well established in many parts of the world.

This was an Abridged Standard Bibliographical decentralised application submitted in accordance with Directive 2001/83/EC Article 10a. The active ingredients (drug substances) are well established and literature references are provided in support of the safety and efficacy of the product.

About the product

The combination of paracetamol, guaifenesin and phenylephrine was first registered in the UK on 19 October 1994 (Beechan s All-in-One). This is the basis of this submission under Article 10(a) well-established use. In the current submission paracetamol (500 mg), guaifenesin (100 mg) and phenylephrine hydrochloride (6.1 mg) are used in combination in a capsule. The pharmacokinetics of each drug substance have been well documented in the literature.

Product Name	Beechams Ultra All in One Capsules
Type of Application	Standard Abridged Decentralised (Article 10.1)
Active Substance (INN)	Paracetamol, Guaifenesin and Phenylephrine
Pharmacotherapeutic Classification (ATC)	N02BE51
Pharmaceuctical Form and Strength	Capsules, Hard
Procedure Numbers	UK/H/1128/001/DC
RMS	UK
CMS	IE
Start Date	08/09/2008
End Date	20/01/2009

MA Number	PL 12063/0082
Name and address of MA holder	Wrafton Laboratories Limited Exeter Road, Wrafton Braunton, Devon EX33 2DL

II. QUALITY ASPECTS

Quality aspects
The chemical-pharmaceutical documentation and Expert Report in relation to Beechams Ultra All in One Capsules are of sufficient quality in view of the present European regulatory requirements.

Drug substance

Each active substance manufacturer holds a certificate of suitability of the Ph Eur monograph and valid copies of the certificates are provided. All aspects of the manufacture and control of each active ingredient are therefore covered by the respective certificate of suitability. Satisfactory batch analysis results for each active ingredient was also provided. Stability of each active ingredient has been demonstrated up to the respective re-test periods.

Drug Product

Formulation development of the drug product has been described, the choice of excipients is justified and their functions explained. All the excipients are commonly used in the manufacture of solid oral dosage forms and have been used by the applicant in previously licensed products. The excipients are all of pharmacopoieal grade and comply with their respective Ph Eur monographs. The product is a dry powder mix filled into size 0 hard gelatin capsules. The capsules are procured from known sources and TSE certificates have been provided for all the sources of gelatin used in the capsules. The colourings used in the capsules comply with Commission Directive 95/45/EC regarding purity criteria for colours used in foodstuffs.

The finished product manufacturer has appreciable experience in the manufacture of similar products and hence of the manufacturing process. Development of the manufacturing process is concisely described starting with a similar licensed product as a reference formulation and optimising the excipient mix to improve process performance. The optimised manufacturing process and formulation was satisfactorily validated on three pilot scale batches and the first three production scale batches will be validated accordingly.

The finished product specifications at release and shelf life are adequate to assure product quality throughout shelf life and are in accordance with ICH guideline Q 6A.
Validations of the analytical methods have been presented. Batch analyses results have been provided for three pilot scale batches and conform to the finished product specification. The levels of impurities detected at release and shelf life were generally below the validated limits of quantification.

Stability data is provided for the three pilot scale batches manufactured during product development. The conditions used in the stability studies are according to the ICH stability guideline. Results have been provided for 6 months at 40 ± 2 °C / 75 ± 5% RH, 12 months at 30 °C ± 2 °C / 65% RH ± 5% and 18 months at 25 ± 2 °C / 60 ± 5% RH. There was no significant change in any of the tested parameters with the exception of observed degradation of the capsule body after 3 months at 40 ± 2 °C / 75 ± 5% RH conditions of storage. The results support the proposed shelf life of 24 months.

III. NON-CLINICAL ASPECTS

No new non-clinical data have been provided. The pharmacodynamics, pharmacokinetics and toxicology of both paracetamol, guaifenesin and phenylephrine hydrochloride are well established and the non-clinical dossier is based on a review of published literature. An environmental risk assessment has been provided.

IV. CLINICAL ASPECTS

Pharmacokinetics
The pharmacokinetics of paracetamol, guaifenesin and phenylephrine are well known. No new data has been submitted and none is required.

Clinical efficacy and Clinical safety

No Module 5 is submitted. This is a bibliographical submission as required by Article 10(a). The clinical overview reviews 33 publications the most recent dating from 2006. No bio-availability and/or bio-equivalence studies or safety data are presented for the same reasons.

Conclusion:

The clinical overview adequately covers the needs of this submission.

A Marketing Authorisation may be granted.

VI. REVISION DATE

December 2021

VII. UPDATES

Scope	Procedure number	Product information affected	Date of start of the procedure	Date of end of procedure	Approval/ non approval
RMS Transfer	From UK/H/1128/001/DC to IE/H/0902/001/DC	N/A	N/A	N/A	Approved 17/05/2019